My Companies
Notification
Account
Log Out
Login
Signed 10-year take-or-pay CDMO agreement with undisclosed European alternative-protein innovator for Ujjain fermentation capacity. Production starts at existing four 100kL facility, followed by new dedicated plant of several hundred thousand litres with expansion options to millions of litres. Context: converts advanced Europe term-sheet to definitive starting idle-capacity conversion.
Symbiotec Arm Signs Exclusive US Deal For Two DCV Injectables
Symbiotec Pharmalab Recreates Promoter Pledges Covering 12.82% Of Share Capital
Symbiotec Pharmalab Discloses 5.44% Promoter Share Pledge To Beacon Trusteeship
Symbiotec Pharmalab Sees Mirae Asset Mutual Fund Acquire 5.44% Stake